EDGC
245620KOSDAQ자연과학 및 공학 연구개발업37.5 / 100
Reference Date: 2026-04-13
Company InformationBased on 2025 Annual Report
Business Overview
EDGC is a global bio-genomics big data company established in 2013 as a joint venture between a Korean medical institution and the U.S.-based Diagnomics, Inc. It offers key services such as NGS-based genomic analysis, personalized diagnostic tests, and liquid biopsy (OncoCatch), along with its flagship services 'YouWho' for genetic ancestry analysis and 'NICE' for non-invasive prenatal testing. In 2021, EDGC acquired a Canadian health supplement manufacturer to expand its customized health supplement business, aiming to develop integrated precision medicine solutions through genomic-based drug development.
Number of Employees
63people
Average Salary
43.6M KRW
Score Calculation Basis
Detailed Financial Score
4.3x industry avg (risky)
6.6x industry avg (excellent)
64.4x industry avg (risky)
Avg ▼35.8% (2-year basis)
Avg ▼16.6% (2-year basis)
Avg ROE -150.7% (declining, 2yr)
Detailed News Sentiment
- NegativeEDGC, 회생절차 진행…감자·유상증자 등 자본 구조조정 단행
EDGC가 회생절차에 따라 무상감자 및 유상증자를 결정하며 자본 구조조정을 단행한다는 소식입니다.
Detailed Momentum
52w mid range (50%)
1m 0% (flat)
Volume flat
Detailed Disclosure
- Neutral[기재정정]최대주주변경2026-04-10
- Neutral사업보고서 (2025.12)2026-04-08
- Neutral[기재정정]사업보고서 (2024.12)2026-04-07
- Neutral주식등의대량보유상황보고서(일반)2026-03-30
- Neutral사업보고서제출기한연장신고서 (2025.12)2026-03-24
